Firms form Alzheimer's test deal:
This article was originally published in Clinica
Applied NeuroSolutions has linked up with fellow Illinois firm Nanosphere to develop a sensitive and specific early test for Alzheimer's disease. Nanosphere's Biobarcode technology for ultra-sensitive protein detection will be combined with Applied NeuroSolutions' biomarkers, which have been shown to be 85-95% accurate in detecting the disease. There are currently no US FDA-approved diagnostic tests for detecting Alzheimer's disease; it can only be confirmed post-mortem, Applied NeuroSolutions (Vernon Hills) and Nanosphere (Northbrook) noted.